Clinical Trials Logo

Depressive Disorder, Major clinical trials

View clinical trials related to Depressive Disorder, Major.

Filter by:

NCT ID: NCT03242213 Recruiting - Clinical trials for Major Depressive Disorder

Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement

Start date: July 20, 2017
Phase: N/A
Study type: Interventional

The current randomized controlled trial is a pilot study that will assess the effectiveness and feasibility of a mobile phone application intervention. The objective is to determine whether the use of a mobile health application for patient self-management of depression improves patient-provider engagement for patients diagnosed with major depressive disorder.

NCT ID: NCT03237078 Not yet recruiting - Clinical trials for Major Depressive Disorder

Lactobacillus Plantarum PS128 in Patients With Major Depressive Disorder and High Level of Inflammation

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Recent studies have suggested that gut-brain axis may be one of the mechanisms of major depression disorder (MDD). In animal studies, alteration of gut microbiota can affect animal's depression or anxiety-like behavior, brain neurochemistry and inflammation. In human studies, the composition of gut microbiota is different between patients with MDD and healthy controls. In addition, supplementation of probiotics can improve mood status in community and clinical participants. Inflammation is one of possible pathway to connect gut and brain. Gut permeability and inflammation level are higher in patients with MDD. Lactobacillus plantarum PS128 in one of bacteria extracted from traditional fermented food, Fu-Tsai. It can alleviate depressive-like behavior reduce inflammation level in maternal separation mice. This study is an 8-week open trial to investigate the effects of Lactobacillus plantarum PS128 on psychophysiology in patients with MDD and higher level of inflammation. This is a two-phase study. In the first phase, we will recruited patients fulfilling the following inclusion criteria: Age 20-65; fulfill Diagnostic and Statistical Manual of Mental Disorders fifth version (DSM-V) criteria of major depressive episode in recent 2 years; Psychotropics including antidepressants, antipsychotics and hypnotics have been kept unchanged for at least 3 months. The exclusion criteria are: comorbid with schizophrenia, bipolar disorder, or other substance use (except tobacco) disorder; having active suicidal or homicidal ideation; known allergy to probiotics; comorbid with hypertension, diabetes mellitus, irritable bowel syndrome, inflammatory bowl disease, liver cirrhosis, or autoimmune diseases; known active bacterial, fungal, or viral infections in one month; use of antibiotics, steroid, immunosuppressants, probiotics, or synbiotics in the month before collecting blood and fecal samples; pregnant or lactating women; who state to have dietary pattern changed or in diet within previous two months. Those hs-CRP > 3 mg/L in the first screen will be invited into the second phase intervention. In the second phase intervention, we will give eligible patients Lactobacillus plantarum PS128 for 8 weeks, and compare depression symptoms, gut microbiota, gut inflammation and permeability, and serum inflammation level before and after intervention.

NCT ID: NCT03230682 Recruiting - Clinical trials for Major Depressive Disorder

Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder

Start date: July 25, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Early improvemrnt, decreased 20% in the 17 items of Hamilton Depression Rating Scale (HAMD-17) at the second week of the treatment of major depression disorder (MDD), can arguably predict the remission at the 12th week. Our observation study including 80 MDD patients will access resting-state function MRI to finding factors which infuencing early improvemrnt, respone and remission of antidepressants.

NCT ID: NCT03228953 Recruiting - Clinical trials for Major Depressive Disorder

Pharmacogenomic Testing in Major Depressive Disorder

Start date: August 2017
Phase: N/A
Study type: Interventional

This is a two-arm double-blind prospective randomized controlled trial (RCT) to evaluate clinical impact of pharmacogenomic testing on the treatment of major depressive disorder. Participants will be randomly assigned to two groups: pharmacogenomic-guided therapy group (guided group) and treatment as usual group (TAU group). The primary hypothesis is the pharmacogenomic-guided treatment group will demonstrate significantly higher percent improvement in depression score compared to treatment-as-usual group.

NCT ID: NCT03227224 Not yet recruiting - Clinical trials for Depressive Disorder, Major

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Start date: September 1, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.

NCT ID: NCT03222752 Recruiting - Clinical trials for Major Depressive Disorder

Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder

Start date: June 5, 2017
Phase: N/A
Study type: Interventional

Efficacy of Cranial Electrotherapy Stimulation (CES) for the treatment of Major Depressive Disorder

NCT ID: NCT03219008 Not yet recruiting - Depressive Disorder Clinical Trials

Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

STEP-MDD
Start date: August 1, 2017
Phase: Phase 4
Study type: Interventional

Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition,diagnosis,and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases,such as nervous system diseases, cardiovascular diseases,endocrine diseases, have the high comorbidity of depressive disorder. However,there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology,and neuroimaging technology etc.

NCT ID: NCT03207503 Not yet recruiting - Clinical trials for Depressive Disorder, Major

Neurobehavioral Mechanisms of Emotion Regulation in Depression Across the Adult Lifespan

Lifespan
Start date: August 2017
Phase: N/A
Study type: Observational

Test a model of age related changes to brain circuitry and precognitive performance as predictors of emotion regulation ability and depressive symptoms

NCT ID: NCT03207438 Active, not recruiting - Clinical trials for Depressive Disorder, Major

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Start date: April 2006
Phase: Phase 4
Study type: Interventional

In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis. Hypothesis 1: Is low-dose quetiapine (50 mg/day) more effective for patients with depression who have insomnia at treatment baseline? (Stated differently: is low-dose quetiapine 50 mg/day effective as monotherapy for patients with depression regardless of whether or not they have insomnia at baseline?). Hypothesis 2: Is high-dose quetiapine (150 - 300 mg/day) more effective for patients presenting with melancholic depression at treatment baseline?

NCT ID: NCT03203954 Recruiting - Clinical trials for Major Depressive Disorder

Testing the Neuroscience of Guided Learning in Depression

Start date: May 1, 2016
Phase: N/A
Study type: Interventional

Major depression is a prevalent and impairing illness. To better understand the basic science and treatment of depression, the investigators study the behavioral and brain processes associated with learning in depression and how potential disruptions in learning may be repaired. Understanding different methods that change learning may lead to novel treatments that contribute to recovery in people with depression.